Who we are

We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.

Our Technology

DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells.

Experienced leadership

Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 platform technology.

Management board


Frank Michalargias


Public company CFO with broad industry experience including senior positions with Unilever and Huhtamaki Oy

Board of directors


Sławomir Majewski

Vice Rector of the Medical University of Warsaw, Corresponding Member of the Polish Academy of Science


Artur Gabor

Founder Gabor & Gabor
Supervisory Board Chairman – Sfinks Polska S.A. and Grupa LEW S.A.


Ireneusz Fafara

Over 30 years of experience in financial and industrial sector. Former General Director of the Supervisory Board of ORLEN Lietuva.

Scientific and Strategic Advisory Board(SSAB)


Kazimierz Roszkowski-Sliz

Dr. Roszkowski-Sliz is the Director and Head of Clinical of the National Tuberculosis and Lung Diseases Research Institute in Poland; National Consultant for Lung Diseases, Ministry of Health; Chairman of Scientific Council of Ministry of Health; and Chairman of the Scientific Council of the National Center Institute of Oncology Poland. Dr. Roszkowski-Sliz is an expert in the treatment of lung diseases.


Robert Gillies

Dr. Robert Gillies holds the Martin Silbiger Endowed Chair and is Chair of the Department of Cancer Physiology and Vice-Chair (Research) of the Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute; and Professor Emeritus, Departments of Radiology and Biomedical Engineering, College of Medicine University of Arizona. He is past president of the Society for Molecular Imaging and has served on numerous grant review panels for the NIH and the DoD, consulting on cancer physiology and imaging. Dr. Gillies is an expert in tumor acidity and has published extensively in this area of research.


Heman Chao

Biochemist with expertise in protein drug development. Previous role with Sensium Technologies Inc.


Frank Gary Renshaw

Dr. Renshaw is the Chief Medical Officer of Zhejiang DTRM Biopharma Co. Ltd. Previous roles included Medical Oncology Director at Eisai; Global Executive Director Level II, Oncology and Hematology R&D at Celgene Corporate; Executive Director at Celsion Corporation and Global Clinical Lead; and Clinical Pharm Lead at Bayer Health Care Corporation. Dr. Renshaw participates in a number of oncology industry committees and task forces